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Abstract
Objective: The Parkinson’s Progression Markers Initiative (PPMI) is an obser-
vational, international study designed to establish biomarker-defined cohorts
and identify clinical, imaging, genetic, and biospecimen Parkinson’s disease
(PD) progression markers to accelerate disease-modifying therapeutic trials.
Methods: A total of 423 untreated PD, 196 Healthy Control (HC) and 64
SWEDD (scans without evidence of dopaminergic deficit) subjects were
enrolled at 24 sites. To enroll PD subjects as early as possible following diag-
nosis, subjects were eligible with only asymmetric bradykinesia or tremor plus
a dopamine transporter (DAT) binding deficit on SPECT imaging. Acquisition
of data was standardized as detailed at www.ppmi-info.org. Results: Approxi-
mately 9% of enrolled subjects had a single PD sign at baseline. DAT imaging
excluded 16% of potential PD subjects with SWEDD. The total MDS-UPDRS
for PD was 32.4 compared to 4.6 for HC and 28.2 for SWEDD. On average,
PD subjects demonstrated 45% and 68% reduction in mean striatal and con-
tralateral putamen Specific Binding Ratios (SBR), respectively. Cerebrospinal
fluid (CSF) was acquired from >97% of all subjects. CSF (PD/HC/SWEDD
pg/mL) a-synuclein (1845/2204/2141) was reduced in PD vs HC or SWEDD
(P < 0.03). Similarly, t-tau (45/53) and p-tau (16/18) were reduced in PD
versus HC (P < 0.01), Interpretation: PPMI has detailed the biomarker signa-
ture for an early PD cohort defined by clinical features and imaging biomark-
ers. This strategy provides the framework to establish biomarker cohorts and
to define longitudinal progression biomarkers to support future PD treatment
trials.
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Introduction
Utilizing biomarkers to define optimal study cohorts and
identifying reliable and well-validated biomarkers for
Parkinson’s disease (PD) progression are crucial to
advance research to develop therapeutics that may slow
or prevent PD symptoms and pathology.1,2 The Parkin-
son’s Progression Markers Initiative (PPMI) is an obser-
vational, international, multicenter study designed to
establish biomarker-defined cohorts, identify PD progres-
sion biomarkers to improve understanding of disease
etiology and course, and to provide the necessary tools
to enhance the likelihood of success of PD disease-
modifying therapeutic trials (ClinicalTrials.gov Identifier:
NCT01141023). PPMI is a collaborative effort of PD
researchers with expertise in biomarker development, PD
clinical study design and implementation, bioinformatics,
statistics, and data management.3 The study is a public-
private partnership of academic researchers, The Michael
J. Fox Foundation for Parkinson’s Research (MJFF), and
pharmaceutical and biotech industry partners. The overall
goal of PPMI is to investigate novel methods to establish
longitudinal PD cohorts to examine clinical, imaging,
genetic, and biospecimen PD progression markers that
individually or in combination will rapidly demonstrate
interval change in PD patients in comparison to Healthy
Controls (HC) or in sub-sets of PD patients defined by
baseline assessments, genetic mutations, progression mile-
stones, and/or rate of clinical, imaging, or biospecimen
change.
PPMI has established standardized protocols for acqui-
sition, transfer, and analysis of clinical, imaging, genetic,
and biospecimen data that can be used by the PD
research community. Importantly, PPMI is committed to
data and biospecimen sharing. PPMI data are available to
the research community on the PPMI website as it is col-
lected. As of December 2017, there are more than 1.5 mil-
lion downloads of data, and more than 100 request
applications for PPMI biospecimens reviewed by the
PPMI Biospecimen Review Committee. All PPMI stan-
dardized protocols and data are available atwww.ppmi-inf
o.org.
A major initial goal of PPMI was to establish a biomar-
ker-defined early PD cohort to be followed longitudinally
to identify progression biomarkers. Early and accurate
diagnosis of PD subjects enabling enrollment as soon as
possible following diagnosis would potentially allow
assessment of subjects in clinical trials for as long as pos-
sible prior to initiating PD medications. This strategy is
crucial to the early investigation of novel disease-modify-
ing PD therapies. We recognize that some of these data
have been part of other publications that have utilized
PPMI open access data. In this paper from the PPMI
steering committee, we comprehensively detail the meth-
ods utilized to establish the biomarker-defined PD cohort
and the baseline clinical, imaging, and CSF characteristics
of the cohort.
Methods
Study organization and governance
The PPMI steering committee is responsible for all
aspects of study conduct and directs the study through
the clinical, imaging, genetics, bioanalytic, biorepository,
statistics, and bioinformatics cores. The steering commit-
tee includes PD clinical and biomarker experts, study core
leaders, MJFF, and industry scientists.
Study participants
PD and HC subjects of similar age and gender from 24
study sites in the US (18), Europe (5) and Australia (1)
were enrolled after obtaining informed consent. We
acknowledge that the early PD cohort likely includes a
small number of subjects with other DAT deficit parkin-
sonian syndromes such as progressive supranuclear palsy
(PSP), multiple system atrophy (MSA) and cortical basal
syndrome (CBS), which may be indistinguishable from
PD at the earliest stages of disease. At each study visit,
the investigators reassess the subject diagnosis to identify
any non-PD subjects.
This study was conducted in accordance with the Dec-
laration of Helsinki and the Good Clinical Practice (GCP)
guidelines after approval of the local ethics committees of
the participating sites. At enrollment, PD subjects were
required to be age 30 years or older, untreated with PD
medications (levodopa, dopamine agonists, MAO-B inhi-
bitors, or amantadine), within 2 years of diagnosis,
Hoehn and Yahr <3, and to have either at least two
of resting tremor, bradykinesia, or rigidity (must have
either resting tremor or bradykinesia) or a single
asymmetric resting tremor or asymmetric bradykinesia.
All PD subjects underwent dopamine transporter (DAT)
imaging with 123I Ioflupane or vesicular monoamine
transporter (VMAT-2) imaging with 18F AV133 (Aus-
tralia only) and were only eligible if DAT or VMAT-2
imaging demonstrated dopaminergic deficit consistent
with PD in addition to clinical features of the disease.
Study investigators evaluated enrolled PD subjects to
assess absence of current or imminent (6 months) disabil-
ity requiring PD medications, though subjects could
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initiate PD medications at any time after enrollment if
the subject or investigator deemed it clinically necessary.
Those subjects screened as potential PD subjects who
were ineligible due to DAT or VMAT-2 scans without
evidence of dopaminergic deficit (SWEDD) were eligible
to be enrolled in a SWEDD cohort.4 HC subjects were
required to be age 30 years or older without an active,
clinically significant neurological disorder or a first-degree
relative with PD. All enrolled subjects agreed to complete
all study evaluations, including lumbar puncture.
PD and SWEDD subjects were excluded if they had a
clinical diagnosis of dementia or had taken PD medica-
tions within 60 days of baseline or for longer than
60 days in total. HC subjects were excluded if they had a
Montreal Cognitive Assessment (MoCA) total score ≤26.
All subjects were excluded if they were treated with neu-
roleptics, metoclopramide, alpha methyldopa, methylphe-
nidate, reserpine, or amphetamine derivative within
6 months or were currently treated with anticoagulants
that might preclude safe completion of the lumbar punc-
ture.
Study assessments
All subjects underwent a comprehensive battery of clinical
testing, imaging assessments, blood, urine, and cere-
brospinal fluid (CSF) biospecimen collection at baseline.
Planned follow-up for all subjects included clinical motor
assessments at 3-month intervals during year one fol-
lowed by 6-month intervals. Cognitive and behavioral
assessments were conducted at 12-month intervals for all
subjects. DAT or VMAT-2 (Australia only) imaging was
conducted at 12, 24, and 48-month visits for PD subjects,
24-month visits for SWEDD subjects, and only at baseline
for HC subjects. All subjects underwent MRI at baseline,
and approximately 50% of the subjects (based on the
potential to standardize their MRI acquisition) underwent
more extensive MRI with diffusion tensor imaging (DTI)
at baseline and at similar longitudinal intervals to DAT
imaging. All subjects had planned follow-up with blood
collection at 3-month intervals during year one followed
by 6-month intervals, CSF collection at six, and 12-month
visits, followed by 12-month intervals. All subjects under-
went urine collection at 12-month intervals.
Clinical assessments included Movement Disorders
Society-Unified Parkinson Disease Rating Scale (MDS-
UPDRS) and Hoehn and Yahr scales.5 Global cognition
was assessed with the MoCA.6,7 Cognitive testing included
the Hopkins Verbal Learning Test-Revised (HLVT-R) to
assess memory; Benton Judgment of Line Orientation
(JOLO) 15-item version to assess visuospatial function;
Symbol-Digit Modalities Test (SDMT) to assess process-
ing speed-attention; and Letter-Number Sequencing
(LNS) and semantic (animal) fluency to assess executive
abilities-working memory.8–12 Published norms were
applied. Neurobehavioral testing included the Geriatric
Depression Scale (GDS), State – Trait Anxiety Inventory
(STAI), and Questionnaire for Impulsive-Compulsive
Disorders (QUIP).13–15 Additional assessments included
Epworth Sleepiness Scale and a REM sleep behavior disor-
der (RBD) questionnaire to assess sleep behavior, Scales
for Outcomes in Parkinson’s Disease-Autonomic
(SCOPA-AUT) to assess autonomic function, and the 40-
item University of Pennsylvania Smell Identification Test
(UPSIT) to assess olfactory function..16–19
All subjects had dopaminergic imaging with either 123I
Ioflupane targeting the dopamine transporter (DAT-
SPECT) or 18F AV133 (Australian site only) targeting the
vesicular monoamine transporter (VMAT-PET) at screen-
ing according to the imaging technical operations manual
(www.ppmi-info.org).20–24 To ensure technical standard-
ization across multiple sites and cameras employed in this
study, a central core imaging laboratory developed a pro-
gram for technical qualification, quality assurance, and
ongoing camera quality control. An anthropomorphic
striatal phantom was filled with 123-I and acquired with
the same protocol used for PPMI subjects. This phantom
was used to check for the accuracy and resolution of the
reconstructed image volume, as well as to develop a site-
specific attenuation correction factor (l) to be applied to
the data at the imaging core lab.
All imaging data were visually read and analyzed quan-
titatively at the central core imaging laboratory at the
Institute for Neurodegenerative Disorders (IND) in New
Haven, CT. For DAT studies, subjects were injected with
185 MBq of 123I Ioflupane then imaged 4  0.5 h
postinjection for 30–45 min. Sites transferred raw projec-
tion data to the central core imaging laboratory for qual-
ity control, including assessment for motion, standardized
reconstruction, attenuation correction, and quantification.
SPECT raw projection data were imported to a HERMES
(Hermes Medical Solutions, Stockholm, Sweden) system
for iterative (HOSEM) reconstruction. This was per-
formed for all imaging data to ensure consistency of the
reconstructions. Iterative reconstruction was performed
without any filtering applied. The HOSEM reconstructed
files were then transferred to PMOD (PMOD Technolo-
gies, Zurich, Switzerland) analysis software for subsequent
processing. Attenuation correction ellipses were drawn on
the images and a Chang 0 attenuation correction were
applied to images utilizing a site-specific mu that was
empirically derived from phantom data acquired during
site initiation for the study., A standard Gaussian 3D
6.0 mm filter was applied after attenuation correction was
completed. These files were then normalized to a SPECT
ioflupane reference template in standard Montreal
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Neurologic Institute (MNI) space to ensure standard
anatomical alignment across scans. Intramodality spatial
normalization using the standard template provided the
most robust normalizations for the ioflupane DAT-
SPECT image volumes. Subsequently, the transaxial slice
with the highest striatal uptake was identified and the
eighth hottest striatal slices around it were averaged to
generate a single slice image. For VMAT-PET studies,
subjects were injected with 222 MBq of 18F AV133 then
imaged for 10 min at 50 min postinjection and for
10 min at 80 min postinjection, for a total of 20 min of
imaging. PET data were imported to a PMOD system for
processing and analysis following technical and scientific
quality control, including assessment for motion per-
formed at the central core imaging laboratory. The PET
volume was co-registered to the subject’s MRI. The MRI
was normalized to standard MNI space and the transfor-
mations from that normalization applied to the co-regis-
tered PET volume to ensure standard anatomical
alignment across scans. A standardized striatal template
created at the central core imaging laboratory was then
placed on the normalized MRI volume. Volume of inter-
est (VOI) placement was adjusted on images with atro-
phy, or if the VOI template did not exactly align.
All images were visually interpreted as either positive
or negative for DAT or VMAT-2 deficit25 by two experi-
enced, independent nuclear medicine readers blinded to
clinical diagnosis. Visual interpretation for both DAT and
VMAT-2 images required the reader to interrogate the
intensity and symmetry of radiotracer uptake in left and
right putamen to determine whether the pattern was con-
sistent with a dopaminergic deficit. Criteria for abnormal-
ity for DAT were as indicated on the product label.
Similar criteria were also used for VMAT-2. In the event
of disagreement between the readers’ visual interpretation,
a consensus review process was implemented for the final
scan interpretation. Subjects were enrolled in the PD,
SWEDD, or HC cohorts based on a combination of visual
interpretation of DAT or VMAT-2 imaging and the clini-
cal eligibility criteria (above).
Quantitative outcomes were acquired for all images.
For DAT VOI were placed on the left and right caudate,
left and right putamen, and the occipital cortex (reference
tissue) (Fig. S1). Count densities for each region were
extracted and used to calculate SBRs for each of the four
striatal regions. SBR was calculated as (target region/refer-
ence region)-1. For VMAT-2 quantitative measurements
(count densities or average standard uptake value (SUV)
per voxel) were extracted and used to calculate SBRs for
all of the striatal areas (left and right caudate, anterior
putamen, and posterior putamen). SBR was calculated as
(target region/reference region)-1. The reference region
was the occipital lobe. Note that the posterior putamen
for VMAT-2 was equivalent to the putamen reported for
DAT. DAT and VMAT-2 striatal regional SBR were char-
acterized as either ipsilateral or contralateral to the motor
symptoms as defined by the MDS-UPDRS. If there was
no motor asymmetry (<5%), the right side was called
ipsilateral by convention.
All subjects underwent MRI imaging at baseline to
identify significant non-PD pathology. Subjects from 10
study sites had a standardized MRI acquisition protocol
including a 3D magnetization prepared rapid gradient
echo (MPRAGE) sequence for imaging anatomical details
and a cardiac-gated 2D single-shot echo-planar DTI
sequence for mapping brain water diffusion requiring a 3
Tesla Siemens Trio (these data have been reported else-
where).26
Baseline blood (plasma, whole blood, RNA) and CSF
were collected as detailed in the PPMI biologics manual
(www.ppmi-info.org). Blood samples were collected in
the morning after fasting (all times of collection and fast-
ing status were recorded). CSF (15–20 mL) was collected
into siliconized polypropylene tubes and centrifuged at
2000g for 10 min at room temperature, then transferred
into 1.5 mL precooled siliconized polypropylene aliquot
tubes followed by immediate freezing on dry ice. All fro-
zen blood, plasma, and CSF were shipped overnight to
the PPMI Biorepository Core laboratories (Coriell, Cam-
den NJ, US; Indiana University, IN, US; BioRep, Milan,
Italy).
Measurements of Ab1–42, T-tau, and P-tau181 were
obtained for CSF samples at the University of Pennsylvania
using the multiplex Luminex xMAP platform (Luminex
Corp: Austin, Texas, USA) with research-use-only Fujire-
bio-Innogenetics INNO-BIA AlzBio3 immunoassay kit-
based reagents (Innogenetics Inc: Harvard, MA, USA) from
a single lot as described previously.27,28 All standards, aque-
ous controls, and CSF samples (including 2 CSF pools for
quality control, 75 lL each) were analyzed in duplicate in
each run.27,28 The reported values were calculated as the
arithmetic mean of the concentration of the duplicates.
CSF a-syn was analyzed at a central laboratory (Covance,
MA, US) using a commercially available enzyme-linked
immunosorbent assay kit. This kit was developed and opti-
mized for PPMI.29,30 Briefly, 200 lL/well of diluted a-syn
standards (range, 6.1–1500 pg/mL) using reconstituted
stock and diluted duplicate CSF samples (200 lL/well)
were added to the capture antibody–coated plate after
washing the plate four times. After overnight incubation of
the plate at 2–8°C with shaking, 50 lL/well of biotinylated
detector antibody was added followed by incubation for
2 h at room temperature. Diluted streptavidin horseradish
peroxidase was added, and the plate was incubated at room
temperature for an additional 1 h. After washing the plate
four times, a mixture of two different chemiluminescent
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substrates was added and end-point luminescence was read
with a luminometer (Synergy 2; BioTek). The concentra-
tion of a-syn was measured using standard curves with
four-parameter curve fitting. Cross-reactivity with b-syn or
c-syn has not been observed with the antibodies used in
this assay.29,30 CSF hemoglobin was measured at Covance
using an enyzme-linked immunosorbent assay method with
reagents obtained from Bethyl Laboratories according to
the manufacturer’s instruction. Hemoglobin was measured
to assess the extent of blood contamination of CSF samples,
and to control for the possible effect of a-syn coming from
red blood cells on observed CSF levels.31
Blood DNA was extracted, and subjects were genotyped
using ImmunoChip and NeuroX genotyping arrays.
Briefly, the ImmunoChip is an Illumina Infinium based
array that interrogates 196,524 variants. The ImmunoChip
was designed in 2009 by investigators interested in
inflammatory and autoimmune disorders. However, this
content also included ~2000 variants prioritized for fol-
low-up by PD genome-wide association study (GWAS).
The content of the ImmunoChip is available (https://ida.
loni.usc.edu/pages/access/geneticData.jsp) and this plat-
form has been previously described.32 NeuroX was
designed in conjunction with Illumina Inc. and includes
over 240,000 exonic variants, as well as over 24,000 vari-
ants relevant to the study of neurodegenerative disease.
Subsequently, whole-genome sequencing has been com-
pleted on the entire cohort.
Standardization
Prior to activation of sites for subject enrollment, all site
personnel received extensive training related to acquisi-
tion of study data and biospecimen collections to ensure
standardization. This included training for MDS-UPDRS
(all examiners required to complete MDS-UPDRS train-
ing), cognitive and behavioral assessments, electronic data
entry, biospecimen collection and handling, and imaging
acquisition.33 Training was provided either by web-based
instruction and/or in-person by PPMI study core person-
nel. Specific study data and biospecimen acquisition man-
uals (available on www.ppmi-info.org) were developed to
augment site training and ensure ongoing standardization.
All data were routinely subjected to quality control pro-
cesses by study cores. Documentation of standardized
analysis processes are made available at www.ppmi-info.
org.
Data flow and access
All data collected at sites were transferred to the clini-
cal core (Clinical Trials Coordination Center (CTCC),
Rochester, NY), imaging core (Institute for
Neurodegenerative Disorders (IND), New Haven, CT),
and biorepositories (Coriell Institute, NJ, US and subse-
quently Indiana University, IN, US; BioRep, Milan,
Italy). Data for each subject visit were reconciled and
then transferred to the bioinformatics core (Laboratory
of Neuroimaging (LONI), Los Angeles, CA). All data
are made available to the PD research community as
these data are collected. Data can be downloaded from
the website (www.ppmi-info.org) after completion of
the data access application.
Statistical analysis
All analyses were performed by the biostatistics core
(University of Iowa, IA, US). For the findings reported
here, the overall goal of the statistical plan was to com-
pare baseline clinical and biomarker results between
PD, HC, and SWEDD groups and to evaluate associa-
tions between clinical and biomarker data. T-tests or
Chi-square were used for pairwise comparisons of
demographic, clinical, and imaging data in PD, HC,
and SWEDD subjects. Due to skewed distributions of
biospecimen data, nonparametric Mann–Whitney U
tests were used for pairwise group comparisons of these
variables. The total MDS-UPDRS and DAT contralateral
putamen were identified prior to the study as two can-
didate biomarkers with face validity for PD progression.
Thus, we sought to assess the associations between clin-
ical, imaging, and biospecimen variables and baseline
total MDS-UPDRS and DAT SBR (contralateral puta-
men) in PD subjects using multivariable linear regres-
sion models with a backwards selection approach. All
models adjusted for age, gender, and duration of dis-
ease. For model fitting, a covariate was included if it
was associated with an outcome at a significance level
of 0.20 or less after adjustment for age, gender, and
duration of disease. To avoid collinearity issues in the
multivariable models, the following hierarchical rules
were used: for CSF biomarkers, if the individual mark-
ers were significant in the screening models, they were
considered in the multivariable model; the CSF ratios
were only considered if neither of the individual mark-
ers were significant. Similarly, for the DAT SBR vari-
ables, if the contralateral putamen or caudate scores
were significant, they were considered; if not, but the
ipsilateral putamen or caudate were significant, they
were considered. This screening process revealed a set
of potential predictor variables for both outcomes
under consideration. This set of predictor variables
made up an initial “full model.” Subsequently, a back-
wards selection process was used to remove variables
one at a time until all variables remaining in the model
were significant at the 0.10 level. Due to the
1464 ª 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
PPMI-Establishing a PD biomarker cohort K. Marek et al.
exploratory nature of these analyses and a desire to cast
a wide net to suggest areas for further exploration of
any findings, we chose not to adjust for multiple com-
parisons.
Results
A total of 811 subjects (570 PD and 241 HC) were
screened for participation in PPMI. Of the 570 screened
as PD subjects, 423 subjects were enrolled, 30 were
excluded, 36 declined participation following screening,
and 81 (16%) were found to have SWEDD. Subjects with
SWEDD were eligible to participate in the SWEDD
cohort. Of the 81 subjects with a SWEDD, 64 (79%)
agreed to enroll in PPMI, and 16 declined participation
following screening. Of those screened as HC subjects,
196 were enrolled, 31 were excluded, and 14 declined par-
ticipation following screening. Subjects were enrolled in
PPMI at 24 sites (553 at 18 US sites, 124 at 5 European
sites and 6 subjects at 1 Australian site). Enrollment
began June 1, 2010. The duration of the enrollment per-
iod was approximately 32 months (Fig. 1). The average
enrollment rate was 1 subject/month/site for PD subjects
and 0.5 subjects/month for HC subjects. The enrollment
curve for HC subjects (Fig. 1B) reflects that HC subject
enrollment was deliberately slowed for 6 months to
ensure that the PD and HC subject enrollment would be
completed concurrently, and to ensure a reasonable age
and gender balance among the PD and HC cohorts.
Enrollment of SWEDD subjects occurred at a similar rate
to PD subjects throughout the enrollment period. Sub-
jects with SWEDD were enrolled in 22 of 24 sites ranging
from 1 to 6 subjects/site.
The subject demographics (Table 1) confirm that we
were successful in obtaining groups of PD, HC, and
SWEDD subjects who were similar with regard to age
and gender. The entire cohort was overwhelmingly white
and non-Hispanic. The PD and HC subjects were gener-
ally highly educated. By design, HC subjects could not be
first-degree relatives of PD patients. First-degree family
members with PD were slightly more prevalent, and edu-
cation levels were significantly lower, among SWEDD
compared to PD subjects.
The number of PD features (signs and symptoms) at
enrollment for PD and SWEDD subjects is indicated in
Table 2. Initial symptom categories were resting tremor,
bradykinesia, rigidity, postural instability, and other (i.e.,
micrographia, hypophonia, sialorhea, dystonia, reduced
arm swing). Study investigators were asked to enroll sub-
jects as early in their disease as possible. Approximately
9% of both PD and SWEDD subjects were enrolled into
the study with a single asymmetric PD feature, and in
those subjects asymmetric resting tremor was the single
feature in more than 80% of these single feature subjects.
The duration of diagnosis at baseline was approximately
7 months and did not differ between PD and SWEDD
subjects. The focus on enrollment of subjects early in dis-
ease raises the possibility that some of the PD subjects
may have other DAT deficit parkinsonian syndromes that
will emerge with follow-up.
The baseline clinical motor, cognitive, and behavioral
characteristics of the PD, HC, and SWEDD cohort are
shown in Table 2. PD subjects had increased total MDS-
UPDRS compared to both HC and SWEDD subjects. As
expected, PD subjects had significantly higher values than
HC subjects on all MDS-UPDRS components. The
SWEDD subjects have increased MDS-UPDRS part 1,
decreased MDS-UPDRS part 3, and similar MDS-UPDRS
part 2 compared to PD subjects. PD subjects demon-
strated modest but clear impairment in tests of cognition,
depression, autonomic function, anxiety, and sleep com-
pared to HC subjects. SWEDD subjects showed modestly
increased depression, anxiety, and abnormalities in auto-
nomic testing compared to PD subjects. The UPSIT was
markedly abnormal in PD subjects, but within the normal
range in both HC and SWEDD subjects. Approximately
40% of PD and SWEDD subjects endorsed questions con-
sistent with RBD compared to 20% of HC subjects. Base-
line cognitive and behavioral status of the PD and HC
cohorts is detailed further in another report.34
DAT imaging data demonstrated a marked reduction
in approximately 45% in SBR in PD compared to HC
subjects (Table 3). All striatal regions were substantially
reduced in PD subjects compared to HC or SWEDD sub-
jects. The greatest reduction in PD at baseline of 67.8%
was found in the contralateral putamen. Regional quanti-
tative imaging values did not differ between SWEDD sub-
jects and HC subjects.
Figure S2 demonstrates the SBR scatterplots for PD
and HC subjects for the mean striatum, ipsilateral and
contralateral putamen, and ipsilateral and contralateral
caudate. To further compare the visual and quantitative
eligibility strategies, a linear discriminant analysis (LDA)
model that included variables representing SBRs for dif-
ferent regions as well as indices of asymmetry (Table S1).
From the model, the region providing the best discrimi-
nation between HC and PD subjects was the contralateral
putamen. Using leave-one-out cross-validation, the func-
tion returned an overall accuracy of 97.4% (Table S1)
and indicates the sensitivity, specificity, and positive and
negative predictive value of the discriminant function
compared to the enrollment eligibility using the visual
read standard. Sensitivity analyses inspecting the conse-
quences of violating the assumptions of equal variability
across cohorts and nonexcessive multicollinearity returned
very similar results (data not shown).
ª 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 1465
K. Marek et al. PPMI-Establishing a PD biomarker cohort
AB
Figure 1. Parkinson’s disease and Healthy control subject enrollment. Enrollment of PD (A) and Healthy Control Subject (B) compared to
predicted enrollment at study start. Note that healthy control subject enrollment was stopped to allow PD and healthy control enrollment to end
simultaneously.
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Biospecimen data for CSF analyzed for Ab1-42, t-tau, p-
tau, and a-syn showed a reduction in t-tau, p-tau, and a-
syn in the PD compared to HC subjects (Table 4). A sim-
ilar reduction in a-syn for PD compared to SWEDD sub-
jects was also apparent, as was a trend for reduction in t-
tau and p-tau for PD compared to SWEDD subjects.
There was also a significant increase in A-Beta in SWEDD
compared to PD subjects. There was a strong correlation
between a-syn and t-tau in both PD and HC subjects
(P < 0.001). Given ongoing optimization of these research
assays as indicated at www.ppmi-info.org, the absolute
values of these CSF analytes may be assay-dependent
when baseline samples are re-assayed, but the relationship
between the PD, HC, and SWEDD subjects remains
stable.
Analysis of subject DNA for common PD mutations
revealed six carriers of the LRRK2 p.G2019S variant, all
PD subjects, nine subjects who carried the GBA p.N370S
risk variant (also called p.N409S) including 7 PD, 1
SWEDD, and 1 HC subjects. There were no subjects with
SNCA duplication or point mutations.
The MDS-UPDRS and DAT contralateral putamen SBR
were identified prior to the study as two candidate
biomarkers with face validity for PD progression. At base-
line, the performance of the clinical, imaging, and
biospecimen markers tested in PPMI were compared to
both MDS-UPDRS and DAT SBR using univariate and
multivariate correlation analysis. Results of the model fit-
ting process for total MDS-UPDRS and DAT contralateral
putamen SBR are provided in Tables 5, 6, respectively.
After adjustment for age, gender, and disease duration,
the final model for total MDS-UPDRS included three pre-
dictors with positive associations (GDS, SCOPA-AUT,
STAI) and three predictors with negative associations
(MoCA, QUIP, contralateral putamen). Similarly, after
adjustment for age, gender, and disease duration, the final
model for DAT contralateral putamen SBR included three
predictors with positive associations (STAI, QUIP,
UPSIT) and a negative association with MDS-UPDRS
total score. In summary, both models demonstrated a sig-
nificant negative correlation between DAT contralateral
putamen SBR and total MDS-UPDRS. There was no cor-
relation between baseline total MDS-UPDRS or DAT con-
tralateral putamen SBR with any of the baseline CSF
biomarkers.
Discussion
PPMI is an international, observational study to establish
biomarker-defined cohorts and to identify PD progression
biomarkers. The primary goal of PPMI is to provide the
necessary tools to support and accelerate PD disease-
Table 1. Subject demographics.
Variable
Enrolled subjects
PD subjects (N = 423) Healthy controls (N = 196)
SWEDD subjects
(N = 64)
P-value
(PD vs. HC)
P-value
(PD vs. SWEDD)
Gender 0.77 0.64
Male 277 (65%) 126 (64%) 40 (63%)
Female 146 (35%) 70 (36%) 24 (38%)
Age 0.33 0.58
Mean 61.7 (33, 85) 60.8 (31, 84) 60.9 (38, 79)
(Min, Max)
Education 0.59 <0.01
<13 years 76 (18%) 29 (15%) 18 (28%)
≥13 years 347 (82%) 167 (85%) 46 (72%)
Ethnicity (self-report) 0.62 0.62
Hispanic/latino 9 (2%) 3 (2%) 2 (3%)
Not hispanic/latino 414 (98%) 193 (98%) 62 (97%)
Race 0.85 0.41
White 391 (92%) 182 (93%) 61 (95%)
Black/African-American 6 (1%) 9 (5%) 1 (2%)
Asian 8 (2%) 1 (1%) 1 (2%)
Other 18 (4%) 4 (2%) 1 (2%)
Family history <0.01 0.14
1st degree family members w/PD 55 (13%) 0 (0%) 15 (23%)
Other family members w/PD 47 (11%) 10 (5%) 6 (9%)
No family members w/PD 320 (76%) 186 (95%) 43 (67%)
PD subject is missing family history.
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Table 2. Comparison of clinical baseline motor and nonmotor data.
Enrolled subjects
Variable PD Subjects (N = 423) Healthy controls (N = 196) SWEDD subjects (N = 64) P-value (PD vs. HC)
P-value
(PD vs. SWEDD)
MDS-UPDRS mean scores
MDS-UPDRS total 32.4 4.6 28.2 <0.01 0.03
MDS-UPDRS part I 5.6 2.9 8.3 <0.01 <0.01
MDS-UPDRS part II 5.9 0.5 5.7 <0.01 0.67
MDS-UPDRS part III 20.9 1.2 14.3 <0.01 <0.01
Hoehn & Yahr N (%) <0.01 0.11
Stage 0 0 (0%) 193 (98%) 0 (0%)
Stage 1 186 (44%) 2 (1%) 37 (58%)
Stage 2 235 (56%) 0 (0%) 27 (42%)
Stage 3–5 2 (0%) 0 (0%) 0 (0%)
Modified SE ADLs scale N/A 0.03
Mean 93.2 N/A 94.8
(Min, Max) (70, 100) (75, 100)
Duration of disease (months from diagnosis) N/A 0.39
Mean 6.7 N/A 7.4
(Min, Max) (0, 36) (1, 37)
MOCA total score <0.01 0.95
Mean 27.1 28.2 27.1
(Min, Max) (17, 30) (26, 30) (17, 30)
GDS total score <0.01 <0.01
Mean 2.3 1.3 3.3
(Min, Max) (0, 14) (0, 15) (0, 14)
SCOPA-AUT total score <0.01 <0.01
Mean 9.5 5.9 13.8
(Min, Max) (0, 39) (0, 20) (2, 44)
State trait anxiety score <0.01 0.07
Mean 65.3 57.1 69.8
(Min, Max) (40, 137) (40, 105) (40, 113)
QUIP 0.77 <0.01
Mean 0.3 0.3 0.6
(Min, Max) (0, 4) (0, 5) (0, 4)
UPSIT raw score <0.01 <0.01
Mean 22.4 34.0 31.4
(Min, Max) (1, 40) (11, 40) (12, 39)
Epworth sleepiness scale 0.28 <0.01
Not sleepy (<10) 357 (84%) 171 (87%) 43 (67%)
Sleepy (10 or above) 66 (16%) 24 (12%) 21 (33%)
RBD questionnaire <0.01 0.67
Negative (less than 5) 263 (62%) 157 (80%) 38 (59%)
Positive (5 or above) 160 (38%) 39 (20%) 26 (41%)
Number of initial PD symptoms N/A 0.04
0 0 (0%) N/A 1 (2%)
1 37 (9%) 6 (9%)
2 138 (33%) 28 (44%)
3 209 (49%) 20 (31%)
4 26 (9%) 9 (14%)
5 3 (1%) 0 (0%)
1 PD subject is missing MDS-UPDRS Total Score, STAI Score, and QUIP.
1 Healthy Control is missing MDS-UPDRS Total Score, Hoehn & Yahr, SCOPA-AUT Score, and Epworth Sleepiness Scale.
Initial symptom categories were resting tremor, bradykinesia, rigidity, postural instability, and other (i.e., micrographia, hypophonia, sialorhea, dys-
tonia, reduced arm swing).
The Initial PD Symptoms P-value is from a test comparing 0–2 versus 3–5 symptoms.
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modifying therapeutic trials. In this report, we have
detailed the methods used to develop a cohort of 423
early untreated PD, 196 HC and 64 SWEDD subjects and
the comprehensive baseline data from these research sub-
jects. A major goal of PPMI is to establish a PD cohort
accurately and as early in the disease as possible. There
are both scientific and practical reasons why an early PD
cohort would likely have the best chance of success in
demonstrating the effects of potential disease-modifying
therapeutics. First, there is increasing evidence that ongo-
ing progression may lessen any potential therapeutic
effect, as pathologic studies indicate significant dopamin-
ergic degeneration present already at 4 years postdiagno-
sis.35 Second, studies designed to evaluate disease-
modifying therapeutics are limited by the slow change in
MDS-UPDRS following treatment with dopaminergic PD
medications, as even subjects early in disease may require
treatment. Therefore, the earlier in disease that subjects
are enrolled, the potentially longer duration these subjects
can be maintained in a therapeutic study while untreated
with PD medications.
In our study, we enrolled subjects using two novel
strategies. All subjects were evaluated with DAT imaging
at baseline to improve accuracy of diagnosis and to allow
subjects to be enrolled earlier in disease with greater con-
fidence in diagnosis. In PPMI, we have predominantly
utilized 123I Ioflupane imaging to determine eligibility,
whereas prior studies that have identified subjects with
SWEDD have utilized 123I ß-CIT or 18F FDopa.36–38
Approximately 16% of subjects with clinical features of
PD who would otherwise have been enrolled as PD
subjects in PPMI were enrolled as SWEDD subjects. We
will acquire longitudinal data on the SWEDD subjects to
further assess diagnostic accuracy. Additionally, we
encouraged all investigators to enroll subjects with single
asymmetric tremor or bradykinesia (understanding that a
single PD feature does not generally meet standard clini-
cal diagnostic criteria)39 in an attempt to encourage early
stage PD enrollment. Approximately 9% of PD subjects
were enrolled with a single PD feature, and over 80% of
those subjects had asymmetric tremor. The PD and
SWEDD subjects were within 7 months of diagnosis,
which is comparable or slightly earlier than other studies
in which SWEDD subjects were included (Elldopa
7 month, Precept 9.5 months).36,37 Importantly, even
with our focus on enrollment of early subjects, the over-
whelming majority of subjects had more than one PD fea-
ture suggesting subjects may develop more than one
feature very soon after disease onset and/or that addi-
tional biomarker strategies may be necessary to accurately
identify subjects even earlier with a single feature. We rec-
ognize that there are potential pitfalls to our early diagno-
sis strategy including errors in diagnosis, especially with
parkinsonian disorders with a DAT imaging deficit such
as PSP, MSA, and CBS.
PPMI enrollment was completed at 24 sites in
32 months despite requirements for very extensive study
assessments for both newly diagnosed PD, HC, and
SWEDD subjects, including frequent and comprehensive
clinical assessments, DAT imaging, and biospecimen col-
lection including CSF. Enrollment was aided by a targeted
recruitment program directed by MJFF that provided
Table 3. Comparison of ioflupane striatal binding ratios (SBR).
Variable
Enrolled subjects
PD subjects (N = 419) Healthy controls (N = 193) SWEDD subjects (N = 62) P-value (PD vs. HC)
P-value
(PD vs. SWEDD)
Contralateral caudate <0.01 <0.01
Mean (SD) 1.838 (0.558) 2.982 (0.625) 2.849 (0.596)
(Min, Max) (0.35, 3.70) (1.32, 5.20) (1.40, 4.18)
Ipsilateral caudate <0.01 <0.01
Mean (SD) 2.154 (0.595) 2.982 (0.625) 2.828 (0.569)
(Min, Max) (0.42, 3.98) (1.32, 5.20) (1.36, 3.83)
Contralateral putamen <0.01 <0.01
Mean (SD) 0.693 (0.270) 2.147 (0.555) 2.068 (0.522)
(Min, Max) (0.12, 2.16) (0.64, 3.89) (0.80, 3.24)
Ipsilateral putamen <0.01 <0.01
Mean (SD) 0.961 (0.382) 2.147 (0.555) 2.066 (0.493)
(Min, Max) (0.22, 2.60) (0.64, 3.89) (0.76, 3.08)
For PD subjects with symmetrical presentation and Healthy Controls, Ipsilateral and Contralateral sides are defined as the mean of the left and
right values.
The six study participants enrolled in Australia did not have DAT obtained. An additional one PD subject and two healthy controls are missing
DAT imaging values at baseline.
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study sites with customized recruitment strategies and
materials. This recruitment strategy is another tool that
could be deployed in future disease-modifying trials.
Importantly, neither the requirement for longitudinal CSF
collection nor DAT imaging was a major deterrent for
enrollment. Subject retention has also been outstanding
with subject dropout <5% when fully enrolled.
A major strength of the PPMI study was the robust
and comprehensive acquisition of within subject clinical,
imaging, genetic, and biospecimen data, and the utiliza-
tion of detailed, standardized protocols for data and
biospecimen acquisition. The study demographics are
consistent with age, gender, education, and ethnicity
typical of large PD clinical trials.35–37 There was no dif-
ference in demographics between US and European
participants. Baseline clinical data demonstrate the
expected increase in the MDS-UPDRS in PD compared
to HC subjects. Comparison of MoCA scores between
PD and HC subjects is limited since HC subjects were
not eligible if MoCA was <27, but approximately 20%
of PD subjects had a baseline MoCA <26 consistent
with early cognitive impairment.40–42 Furthermore, test-
ing for depression, anxiety, and autonomic function
demonstrate impairment in PD compared to HC sub-
jects. These findings are consistent with the notion that
PD results in widespread nervous system dysfunction
even early in the disease course and potentially prior to
motor dysfunction.43–46
DAT imaging for all subjects was analyzed to provide a
quantitative outcome to compare the SBR in PD, HC,
and SWEDD subjects and to characterize the range of
DAT deficit among PD subjects even at the earliest stage
of disease. The eligibility assessment for DAT was based
on visual assessment (the regulatory approved strategy for
123I Ioflupane) and comparison of the visual and quanti-
tative outcomes shows outstanding agreement (Table S1).
The imaging characteristics of the SWEDD subjects con-
firm prior reports that quantitative dopamine transporter
Table 4. Comparison of CSF biomarkers.
Variable
Enrolled subjects
PD subjects (N = 423) Healthy controls (N = 196) SWEDD subjects (N = 64) P-value1 (PD vs. HC) P-value1 (PD vs. SWEDD)
A-Beta 0.39 0.01
Mean (SD) 370.6 (100.39) 377.8 (113.56) 404.3 (106.86)
(Min, Max) (129, 797) (89, 880) (156, 628)
Missing 11 7 5
T-Tau <0.01 0.38
Mean (SD) 44.7 (18.28) 52.5 (27.16) 48.4 (22.98)
(Min, Max) (14, 121) (18, 223) (23, 141)
Missing 15 9 5
P-Tau <0.01 0.34
Mean (SD) 15.6 (10.05) 18.3 (11.69) 17.2 (11.84)
(Min, Max) (4.7, 94) (5.1, 73) (6.1, 71)
Missing 13 7 5
T-Tau/A-Beta 0.02 0.44
Mean (SD) 0.13 (0.06) 0.16 (0.19) 0.13 (0.08)
(Min, Max) (0.04, 0.52) (0.05, 2.12) (0.05, 0.50)
Missing 15 9 5
P-Tau/A-Beta 0.01 0.60
Mean (SD) 0.04 (0.03) 0.06 (0.06) 0.05 (0.03)
(Min, Max) (0.01, 0.51) (0.02, 0.66) (0.02, 0.18)
Missing 13 7 5
P-Tau/T-Tau 0.52 0.97
Mean (SD) 0.37 (0.22) 0.37 (0.19) 0.38 (0.24)
(Min, Max) (0.08, 2.14) (0.13, 1.40) (0.13, 1.23)
Missing 17 9 5
Alpha-Synuclein <0.01 0.03
Mean (SD) 1844.7 (786.13) 2204.3 (1089.11) 2140.8 (1026.70)
(Min, Max) (333, 6695) (593, 8609) (743, 7201)
Missing 11 7 5
b-amyloid (A-Beta), total tau protein (T-Tau), phosphorylated tau protein at Serine 181 (P-Tau181) and alpha-synuclein–assays for CSF analytes run
between September and December 2013.
1P-values from Mann–Whitney U tests.
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assessments in this population are comparable to HC sub-
jects.4 The wide range of DAT deficit among PD subjects
(30–80% loss at baseline) suggest that additional
characteristics may define subsets of PD that manifest PD
symptoms after modest DAT loss compared to those
requiring more severe DAT deficit.36,37,47 Further to the
Table 5. Relationship of baseline MDS-UPDRS total score with nonmotor, imaging, and biospecimen variables for PD subjects.
Variable
Screening
N missing
Multivariable
Estimate (SE) P-value Estimate (SE) P-value
MOCA total score 0.49 (0.279) 0.08 1 0.58 (0.252) 0.022
GDS total score 1.60 (0.246) <0.001 1 0.62 (0.323) 0.055
SCOPA-AUT total score 0.81 (0.097) <0.001 1 0.70 (0.103) <0.001
STAI score 0.22 (0.033) <0.001 1 0.12 (0.042) 0.003
QUIP 1.35 (0.996) 0.18 1 1.85 (0.975) 0.059
UPSIT raw score 0.13 (0.081) 0.11 1 - N.S.
Epworth sleepiness scale 0.67 (0.180) <0.001 1 - N.S.
Mean striatum 6.65 (1.572) <.001 5 Not Included
Mean putamen 9.81 (2.097) <.001 5 Not Included
Mean caudate 4.10 (1.143) <0.001 5 Not Included
Ipsilateral caudate 3.53 (1.081) 0.001 5 Not Included
Contralateral caudate 4.11 (1.126) <0.001 5 - N.S.
Ipsilateral putamen 7.89 (1.649) <.001 5 Not Included
Contralateral putamen 8.31 (2.328) <0.001 5 -8.69 (2.119) <.001
A-Beta 0.008 (0.005) 0.14 12 - N.S.
T-Tau 0.003 (0.006) 0.65 16 Not Included
P-Tau 0.009 (0.005) 0.12 14 - N.S.
T-Tau/A-Beta 0.003 (0.006) 0.59 16 Not Included
P-Tau/A-Beta 0.005 (0.005) 0.36 14 Not Included
P-Tau/T-Tau 0.008 (0.006) 0.17 18 Not Included
Alpha-Synuclein 0.002 (0.005) 0.69 12 Not Included
Urate 0.006 (0.010) 0.52 7 Not Included
Estimates shown are change in 1 unit increase in MDS-UPDRS total score per 1 unit change in predictor variable.
All screening analyses adjust for age, gender, and duration of disease. The multivariable analysis forces age, gender, and duration of disease into
the model.
Table 6. Relationship of baseline DAT imaging contralateral putman SBR with nonmotor, imaging, and biospecimen variables for PD subjects.
Variable
Univariate
N missing
Multivariable
Estimate (SE) P-value Estimate (SE) P-value
MDS-UPDRS total score 0.004 (0.001) <0.001 5 0.004 (0.001) <0.001
MOCA total score 0.002 (0.006) 0.68 4 Not Included
GDS total score 0.007 (0.005) 0.22 4 Not Included
SCOPA-AUT total score 0.0004 (0.002) 0.84 4 Not Included
STAI score 0.001 (0.001) 0.15 5 0.002 (0.001) 0.033
QUIP 0.071 (0.021) <0.001 5 0.066 (0.021) 0.002
UPSIT raw score 0.004 (0.002) 0.014 4 0.004 (0.002) 0.010
Epworth sleepiness scale 0.0002 (0.004) 0.96 4 Not Included
A-Beta 0.0002 (<0.001) 0.067 15 - N.S.
T-Tau 0.0001 (<0.001) 0.24 19 Not Included
P-Tau 0.0001 (<0.001) 0.27 17 Not Included
T-Tau/A-Beta 0.00001 (<0.001) 0.94 19 Not Included
P-Tau/A-Beta <0.0001 (<0.001) 0.68 17 Not Included
P-Tau/T-Tau <0.0001 (<0.001) 0.68 21 Not Included
Alpha-synuclein <0.0001 (<0.001) 0.77 15 Not Included
Urate <0.0001 (<0.001) 0.79 10 Not Included
Estimates shown are change in 1 unit increase in contralateral putamen SBR score per 1 unit increase in predictor variable.
All screening analyses adjust for age, gender, and duration of disease. The multivariable analysis forces age, gender, and duration of disease into
the model.
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point, longitudinal follow-up would be expected to eluci-
date the biomarker signature of these PD sub-sets.
More than 97% of all PPMI subjects had baseline lum-
bar puncture for CSF acquisition. Lumbar punctures were
generally very well tolerated, with headache occurring in
7% of subjects. The procedure was done with atraumatic
needles in 82% of subjects, and that may have con-
tributed to its safety and tolerability.48 PPMI’s success in
acquiring these samples both provides a model for collec-
tion of CSF in future PD studies, as well as a unique
resource for PPMI and the PD research community. Base-
line data demonstrated a reduction in tau, p-tau, and a-
syn in PD compared to HC subjects of about 15%. There
was no difference in A-Beta levels between PD and HC
subjects. Prior studies have shown similar changes in a-
syn and tau in PD subjects,29,49–52 but the PPMI cohort is
unique as a large, prospectively enrolled, previously
untreated PD cohort with well-characterized clinical,
imaging, biospecimen, and genetic biomarkers.
PPMI offers the opportunity to combine and correlate
clinical, imaging, biospecimen, and genetic biomarker
data to establish data-driven PD subtypes. We have exam-
ined the correlation of the baseline biomarkers to MDS-
UPDRS and DAT imaging, the two data anchors to the
PPMI study. There is limited correlation of the clinical
features or biomarkers to baseline MDS-UPDRS or DAT.
Baseline MDS-UPDRS and putamen DAT SBR demon-
strated a modest correlation, as in other clinical studies.
The lack of correlation may reflect the heterogeneity of
presentation, course, and response to therapy, a hallmark
of PD.53–55 The PPMI longitudinal data will examine
whether baseline biomarkers and/or short-term change in
baseline biomarkers are predictive of longitudinal PD
progression outcomes. Developing biomarker-defined
subsets of PD subjects with more consistent disease pro-
gression and ultimately response to therapy is a major
goal of the PPMI study.
This report also provides baseline data comparing the
PD and SWEDD subjects. While recent data from clinical
trials have demonstrated that subjects enrolled with
SWEDD are unlikely to have PD,4 the clinical and bio-
marker characteristics of subjects with SWEDD have not
been reported. The baseline PPMI data suggest that sub-
jects with SWEDD have increased MDS-UPDRS part 1
scores and greater degrees of depression, anxiety, and
autonomic dysfunction compared to PD subjects. These
nonmotor symptoms may contribute to the early suspi-
cion of PD in SWEDD subjects. There was no difference
in cognitive scores between PD and SWEDD subjects and
no difference in UPSIT between HC and SWEDD sub-
jects. Importantly, imaging and CSF biomarker assess-
ments demonstrated that SWEDD subjects were similar to
HC and different from PD subjects. SWEDD subject lon-
gitudinal data will be reported separately.
A major contribution of PPMI was to establish stan-
dardized strategies to acquire and analyze biomarker data
that could be utilized for PPMI and for future clinical tri-
als. Standardized protocols for the collection and analysis
of blood, CSF, imaging, and other study data were
deployed at all sites in PPMI. The acquisition of DAT
data from multiple sites is an example of the technical
challenges in acquiring multicenter quantitative data.
PPMI sought to mitigate the variance in DAT SBR associ-
ated with varied camera, software, and imaging experience
by performing on-site technical visits, including acquisi-
tion of striatal anthropomorphic phantoms to establish
consistent acquisition protocols. Standardized analysis
included central reconstructions of raw projection data,
attenuation correction, and objective quantitative analysis
at a central imaging core laboratory. These methods pro-
duced a high-quality baseline dataset with roughly similar
variance to Ioflupane imaging acquired in single-center
trials.56 The present study suggests it is feasible (as previ-
ously shown in smaller studies) to acquire poolable, mul-
ticenter quantitative data with Ioflupane SPECT.22
All PPMI standardized techniques are available at www.
ppmi-info.org and can be utilized in future clinical studies.
During the past two decades, numerous studies have
tested putative neuroprotective drugs for PD, but none
have clearly demonstrated slowing of disease progression.
A critical lesson learned from these studies is that the lack
of PD biomarkers severely limits the success and interpre-
tation of these trials. Biomarkers of PD progression that
could provide an objective signal indicating study thera-
peutic response within a short treatment interval (and
without the confound of existing PD medications) would
enable more rational and sub-type selective therapeutic
development. The primary goal of PPMI is to establish bio-
marker-defined cohorts and PD progression biomarkers
that could inform clinical studies of PD therapeutics. Com-
bining comprehensive clinical, imaging, biospecimen, and
genetic data enhance the value of each biomarker and pro-
vides the opportunity to combine biomarker data to estab-
lish data-driven PD sub-sets that may ultimately identify
specific PD pathology and/or response to specific PD ther-
apeutics. Ongoing longitudinal follow-up of the PPMI sub-
jects will further address whether singly or in combination
the change in biomarker signature can be used to monitor
disease progression and/or can predict the course of disease
progression. Finally, the ongoing major expansion of the
PPMI study to include prodromal PD cohorts defined by
olfactory loss or RBD with DAT deficit, or common muta-
tions including variants in LRRK2, GBA, and SNCA will
further establish the PD biomarker signature prior to
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diagnosis, fully illuminating the progression of biomarkers
across the entire spectrum of PD.
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